Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the childhood cancer survivor study

被引:292
作者
Sklar, C
Whitton, J
Mertens, A
Stovall, M
Green, D
Marina, N
Greffe, B
Wolden, S
Robison, L
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[3] Fred Hutchinson Canc Res Ctr, Dept Biostat, Seattle, WA 98104 USA
[4] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[6] Roswell Pk Canc Inst, Dept Pediat, Buffalo, NY 14263 USA
[7] Stanford Univ, Med Ctr, Dept Pediat, Palo Alto, CA 94304 USA
[8] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Childrens Hosp, Denver, CO 80218 USA
关键词
D O I
10.1210/jc.85.9.3227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment for Hodgkin's disease (HD) is associated with a variety of thyroid abnormalities, including hypothyroidism, hyperthyroidism, and thyroid neoplasms. Due to the small sample size and short follow-up time of most published studies, it has been difficult to appreciate the full extent of the problem and to characterize the interaction between various patient and treatment variables. To overcome these limitations we have assessed thyroid status in 1,791 (959 males) HD survivors from among 13,674 participants in the Childhood Cancer Survivor Study, a cohort of 5-yr survivors of childhood and adolescent cancer diagnosed between 1970 and 1986. Thyroid abnormalities were ascertained as part of a 22-page questionnaire sent to participants. Survivors were a median of 14 yr (range, 2-20 yr) at diagnosis of HD and a median of 30 yr (range, 12-47 yr) at follow-up. Seventy-nine percent of subjects were treated with radiation (median dose of radiation to the thyroid, 3500 cGy; range, 0.37-5500 cGy). Control data were available from 2,808 (1,346 males) sibling controls. Thirty-four percent of the entire cohort has been diagnosed with at least one thyroid abnormality. Hypothyroidism was the most common disturbance, with a relative risk of 17.1 (P < 0.0001) compared to sibling controls. Increasing dose of radiation, older age at diagnosis of HD, and female sex were all independently associated with an increased risk of hypothyroidism. Actuarial risk of hypothyroidism for subjects treated with 4500 cGy or more is 50% at 20 yr from diagnosis. Hyperthyroidism was reported by 5% of survivors, which was 8-fold greater (P < 0.0001) than the incidence reported by the controls. Thyroid dose of 3500 cGy or more was the only risk factor identified for hyperthyroidism. The risk of thyroid nodules was 27 times (P < 0.0001) that in sibling controls. Female sex and radiation dose to the thyroid of 2500 cGy or more were independent risk factors for thyroid nodules. The actuarial risk of a female survivor developing a thyroid nodule is 20% at 20 yr from diagnosis. Thyroid cancer was diagnosed in 20 survivors, which is 18 times the expected rate for the general population. After taking into account the possibility that some of the relative risk estimates may be exaggerated due to ascertainment bias, abnormalities of the thyroid are still extremely common in young adult survivors of childhood HD, particularly among females treated with high doses of radiation to the neck.
引用
收藏
页码:3227 / 3232
页数:6
相关论文
共 39 条
[1]   TOTAL AND AGE-SPECIFIC INCIDENCE OF GRAVES THYROTOXICOSIS, TOXIC NODULAR GOITER AND SOLITARY TOXIC ADENOMA IN MALMO 1970-74 [J].
BERGLUND, J ;
CHRISTENSEN, SB ;
HALLENGREN, B .
JOURNAL OF INTERNAL MEDICINE, 1990, 227 (02) :137-141
[2]   Breast cancer and other second neoplasms after childhood Hodgkin's disease [J].
Bhatia, S ;
Robison, LL ;
Oberlin, O ;
Greenberg, M ;
Bunin, G ;
FossatiBellani, F ;
Meadows, AT .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :745-751
[3]  
BOULAD F, 1995, BONE MARROW TRANSPL, V15, P71
[4]  
Breslow NE, 1987, IARC SCI PUBLICATION, V82, DOI DOI 10.1016/j.jaad.2016.02.1239
[5]  
Chin D, 1997, CANCER-AM CANCER SOC, V80, P798, DOI 10.1002/(SICI)1097-0142(19970815)80:4<798::AID-CNCR19>3.0.CO
[6]  
2-O
[7]  
CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO
[8]  
2-J
[9]  
Crom DB, 1997, MED PEDIATR ONCOL, V28, P15, DOI 10.1002/(SICI)1096-911X(199701)28:1<15::AID-MPO4>3.0.CO
[10]  
2-W